MX2009013765A - Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos. - Google Patents
Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos.Info
- Publication number
- MX2009013765A MX2009013765A MX2009013765A MX2009013765A MX2009013765A MX 2009013765 A MX2009013765 A MX 2009013765A MX 2009013765 A MX2009013765 A MX 2009013765A MX 2009013765 A MX2009013765 A MX 2009013765A MX 2009013765 A MX2009013765 A MX 2009013765A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- polynucleotides
- polypeptides
- artemin
- related ligands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
Abstract
La invención abarca los polipéptidos, polinucleótidos y anticuerpos para la Artemina y ligandos relacionados incluyendo la Persefina (PSPN). La invención también abarca los vectores de expresión y las células hospederas para producir estos polipéptidos, polinucleótidos o anticuerpos. La invención abarca además el diagnóstico y la terapéutica, especialmente para el cáncer, y particularmente cáncer de mama, cáncer de colon, cáncer de próstata, cáncer endometrial, cáncer de pulmón, cáncer de estómago, cáncer de hígado y otros, que comprende uno o más de los polipéptidos, polinucleótidos, anticuerpos, vectores de expresión, células hospederas descritos, o composiciones de los mismos. Son abarcados particularmente los inhibidores de la Artemina y/o ligandos relacionados, y los usos para estos inhibidores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94639407P | 2007-06-27 | 2007-06-27 | |
PCT/NZ2008/000152 WO2009002193A1 (en) | 2007-06-27 | 2008-06-25 | Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009013765A true MX2009013765A (es) | 2010-02-01 |
Family
ID=40185846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009013765A MX2009013765A (es) | 2007-06-27 | 2008-06-25 | Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos. |
Country Status (8)
Country | Link |
---|---|
US (2) | US20110206673A1 (es) |
EP (1) | EP2164870B1 (es) |
JP (1) | JP2010534195A (es) |
CN (1) | CN101932602B (es) |
AU (1) | AU2008269689A1 (es) |
CA (1) | CA2691166A1 (es) |
MX (1) | MX2009013765A (es) |
WO (1) | WO2009002193A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2012003721A (es) | 2009-09-30 | 2012-06-28 | Evan V Chrapko | Sistemas y metodos para analitica de datos graficos sociales para determinar conectividad dentro de una comunidad. |
EP2488186B1 (en) * | 2009-10-16 | 2017-05-24 | National University of Singapore | Anti-neoplastic uses of artemin antagonists |
US20110099164A1 (en) | 2009-10-23 | 2011-04-28 | Haim Zvi Melman | Apparatus and method for search and retrieval of documents and advertising targeting |
WO2011106897A1 (en) | 2010-03-05 | 2011-09-09 | Chrapko Evan V | Systems and methods for conducting more reliable assessments with connectivity statistics |
WO2011134086A1 (en) | 2010-04-30 | 2011-11-03 | Evan V Chrapko | Systems and methods for conducting reliable assessments with connectivity information |
WO2013097026A1 (en) | 2011-12-28 | 2013-07-04 | Chrapko Evan V | Systems and methods for visualizing social graphs |
US9578043B2 (en) | 2015-03-20 | 2017-02-21 | Ashif Mawji | Calculating a trust score |
US20170235792A1 (en) | 2016-02-17 | 2017-08-17 | Www.Trustscience.Com Inc. | Searching for entities based on trust score and geography |
US9438619B1 (en) | 2016-02-29 | 2016-09-06 | Leo M. Chan | Crowdsourcing of trustworthiness indicators |
US9679254B1 (en) | 2016-02-29 | 2017-06-13 | Www.Trustscience.Com Inc. | Extrapolating trends in trust scores |
US9721296B1 (en) | 2016-03-24 | 2017-08-01 | Www.Trustscience.Com Inc. | Learning an entity's trust model and risk tolerance to calculate a risk score |
FR3058061A1 (fr) * | 2016-10-27 | 2018-05-04 | Selexel | Nouvelle utilisation d'oligonucleotides double brin |
US10180969B2 (en) | 2017-03-22 | 2019-01-15 | Www.Trustscience.Com Inc. | Entity resolution and identity management in big, noisy, and/or unstructured data |
CA3124660A1 (en) * | 2018-12-21 | 2020-06-25 | Gloriana Therapeutics Sarl | Mammalian cell culture-produced neublastin antibodies |
GB2594317B (en) | 2020-04-23 | 2022-05-25 | Univ Johannesburg Witwatersrand | SARS-CoV-2 Diagnostic control compositions |
CN113718029A (zh) * | 2021-10-22 | 2021-11-30 | 中国人民解放军北部战区总医院 | S100a4蛋白在动脉粥样硬化性肾动脉狭窄诊断中的应用 |
CN117700545A (zh) * | 2023-10-26 | 2024-03-15 | 苏州***医学研究所 | 靶向Artemin的抗体及其制备方法和在肿瘤治疗中的应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
ATE59966T1 (de) | 1983-09-26 | 1991-02-15 | Ehrenfeld Udo | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
WO1992020316A2 (en) | 1991-05-14 | 1992-11-26 | University Of Connecticut | Targeted delivery of genes encoding immunogenic proteins |
EP0587738B1 (en) | 1991-06-05 | 2000-08-23 | University Of Connecticut | Targeted delivery of genes encoding secretory proteins |
WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
AU3940293A (en) | 1992-04-03 | 1993-11-08 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
EP0911413A3 (en) | 1992-12-03 | 2000-11-15 | Genzyme Corporation | Minimal adenovirus-based gene therapy vector |
EP0730663B1 (en) | 1993-10-26 | 2003-09-24 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
BR9912819A (pt) * | 1998-07-14 | 2001-05-02 | Janssen Pharmaceutica Nv | Fator de crescimento neurotrófico |
US20020002269A1 (en) * | 1998-09-29 | 2002-01-03 | Jeffrey D. Milbrandt | Artemin, a neurotrophic factor |
PT1626058E (pt) * | 1999-03-08 | 2008-02-15 | Genentech Inc | Composições e métodos para o diagnóstico de tumores |
NZ523206A (en) * | 1999-08-31 | 2004-12-24 | Genentech Inc | Antibodies that bind to tumor gene sequences |
JP2004508019A (ja) * | 2000-07-28 | 2004-03-18 | コンピュジェン インコーポレイテッド | トランスクリプトームの中に場所を占めるrna転写物及びスプライス変異体を検出するためのオリゴヌクレオチドライブラリー |
PT2284266E (pt) * | 2002-11-14 | 2013-12-17 | Thermo Fisher Scient Biosciences Inc | Siarn contra tp53 |
KR20070052694A (ko) * | 2004-01-09 | 2007-05-22 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 유전자 발현을 위한 세포-유형-특이적 패턴 |
US20050186646A1 (en) * | 2004-01-26 | 2005-08-25 | Cruz Miguel A. | Rapid assay to detect ADAMTS-13 activity |
-
2008
- 2008-06-25 CA CA2691166A patent/CA2691166A1/en not_active Abandoned
- 2008-06-25 MX MX2009013765A patent/MX2009013765A/es not_active Application Discontinuation
- 2008-06-25 AU AU2008269689A patent/AU2008269689A1/en not_active Abandoned
- 2008-06-25 US US12/452,291 patent/US20110206673A1/en not_active Abandoned
- 2008-06-25 WO PCT/NZ2008/000152 patent/WO2009002193A1/en active Application Filing
- 2008-06-25 EP EP08779128.1A patent/EP2164870B1/en not_active Not-in-force
- 2008-06-25 CN CN200880104674.9A patent/CN101932602B/zh not_active Expired - Fee Related
- 2008-06-25 JP JP2010514669A patent/JP2010534195A/ja active Pending
-
2014
- 2014-09-19 US US14/491,198 patent/US20150030605A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2008269689A1 (en) | 2008-12-31 |
CA2691166A1 (en) | 2008-12-31 |
EP2164870A1 (en) | 2010-03-24 |
WO2009002193A1 (en) | 2008-12-31 |
EP2164870A4 (en) | 2011-11-23 |
CN101932602A (zh) | 2010-12-29 |
US20150030605A1 (en) | 2015-01-29 |
CN101932602B (zh) | 2017-05-24 |
JP2010534195A (ja) | 2010-11-04 |
EP2164870B1 (en) | 2015-12-09 |
US20110206673A1 (en) | 2011-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009013765A (es) | Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos. | |
CY1120300T1 (el) | Αντισωματα ειδικα στην κλαουδινη 6 (cldn6) | |
CY1118608T1 (el) | Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6 | |
MX340736B (es) | Vacunas y componentes de vacunas para inhibicion de celulas microbianas. | |
PH12013502308A1 (en) | Variant activin receptor polypeptides and uses thereof | |
WO2007081720A3 (en) | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer | |
EA201791940A3 (ru) | Варианты полипептидов рецептора iib активина и их использование | |
DK1893196T3 (da) | Diarylhydantoin-forbindelse | |
WO2005123993A3 (en) | Phage microarray profiling of the humoral response to disease | |
WO2007016548A3 (en) | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer | |
WO2006095086A3 (fr) | Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence. | |
TW200740844A (en) | Novel MAdCAM antibodies | |
EP3838298A3 (en) | Psma binding ligand-linker conjugates and methods for using | |
WO2008121767A3 (en) | Stitched polypeptides | |
EP2487259A3 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers | |
MX2010008096A (es) | Anticuerpos de ferroportina y metodos de uso. | |
WO2006015079A3 (en) | Erm family binding agents and their use in diagnosis and treatment of proliferative conditions | |
WO2016123591A3 (en) | Compositions and methods for treatment and detection of cancers | |
NZ579478A (en) | Epha3 antibodies for the treatment of solid tumors | |
WO2007056049A3 (en) | Molecular profiling of cancer | |
MX2009005293A (es) | Novedosos anticuerpos antiproliferacion. | |
WO2009030770A3 (en) | Methods and tools for prognosis of cancer in er- patients | |
WO2009049966A3 (en) | Methods and tools for prognosis of cancer in her2+ patients | |
WO2008034909A3 (en) | Second line treatment of metastatic hormone refractory prostate cancer using satraplatin | |
ATE435224T1 (de) | Neue piperidinsubstituierte diaminothiazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FA | Abandonment or withdrawal |